ArticlePediatric pulmonology2025
Physical Functioning Report and Pulmonary Function Deficit in Childhood and Adolescent Acute Lymphoblastic Leukemia Survivors: A National Cross-Sectional ALL-STAR Lungs Study.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChildhood acute lymphoblastic leukemia (ALL) survivors face an increased risk of pulmonary function deficit (PFD), which may affect physical functioning. We aimed to evaluate parent proxy- and self-reported physical functioning and the association with PFD and abnormal bronchodilator response ( + BDR) among survivors versus controls.
methodsThis cross-sectional study (February 2019-May 2024) included N = 184 ALL survivors (aged 5-17.9 years) from a national NOPHO ALL2008 protocol-treated cohort (eligible, N = 295) ( ≥ 1 year after treatment cessation) and 207 controls. Physical functioning was assessed using the Paediatric Quality of Life Inventory (PedsQL) questionnaire. Pulmonary function tests (PFTs) identified PFD (abnormal PFT) and +BDR according to ERS/ATS criteria. Ordinal logistic regression and t-test compared groups.
resultsALL survivor parents proxy-reported significantly poorer physical functioning than controls (mean difference [MD] -13.3 95% CI [-16.3; -10.3] to MD -10.3 [-17.2; -3.3], p < 0.001 to p = 0.004), but clinically significant impairments were restricted to parent proxy-reports from survivors treated with high-risk (HR) chemotherapy (MD -19.9 [-29.0; -10.7] to -11.5 [-17.5; -5.6], p < 0.001) and stem cell transplantation (HR-SCT) (MD -24.7 [-30.1; -19.4] to -16.9 [-27.4; -6.5], p < 0.001 to p = 0.002) as well as self-reports from HR (MD -11.2 [-18.9; -3.4], p = 0.006) and HR-SCT survivors (MD -14.5 [-24.1; -4.8], p = 0.004). Among 5-15-year-olds, PFD/ + BDR was associated with significantly poorer parent proxy-reported physical functioning in survivors versus controls (MD -14.3 [-21.2; -7.3], p < 0.001). Significant deficits in these groups related to running, engaging in sports/exercise and lifting heavy objects. PFD/ + BDR was not associated with poorer physical functioning reports within survivors (MD -2.5 [-9.0; 3.3] to 0.1 [-13.7; 13.8], p = 0.36-0.99).
conclusionsPhysical functioning in survivors compared to controls varies with intensity of treatment, most evident in HR and HR-SCT survivors, with impairments linked to PFD and +BDR in the youngest. Among survivors, physical functioning did not align with PFD and +BDR status, highlighting the need for parallel assessment of objective and subjective measures during follow-up. Baseline PFT and tailored follow-up are essential for high-risk groups, to detect PFD early and intervene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.